Telix Pharmaceuticals Ltd
TLXHealthcare|Biotechnology|Australia
$11.14
-0.65 (-5.47%)
About
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Stock Price
-30.8%(1Y)
Pipeline Summary
34 total trials12
Phase 1
8
Phase 2
9
Phase 3
0
Phase 4
Terminated: 4Completed: 10Recruiting: 14NOT_YET_RECRUITING: 2NO_LONGER_AVAILABLE: 2Unknown: 1Active: 1
Active Trials (15)
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04402151Prostate Cancer
Phase 2Recruiting
Enrollment: 50 participants
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
NCT05847348Biochemical Recurrence of Malignant Neoplasm of Prostate
Phase 3Recruiting
Enrollment: 110 participants
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
NCT06537596Soft Tissue Sarcoma
Phase 1Recruiting
Enrollment: 50 participants
PSMA PET Response Guided SabR in High Risk Pca
NCT06044857Prostate Adenocarcinoma
Phase 1Recruiting
Enrollment: 20 participants
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA
Phase 3Recruiting
Enrollment: 204 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
Behrenbruch ChristianBUY
2026-04-2967,935 shares @ $14.67
Recent News
2026-07-07 19:02:51
2026-07-07 11:53:31
2026-07-06 13:33:48
Data last updated: Jul 12, 2026, 07:39 PM